Datapoint: Cigna Adds Humira Biosimilars to Formulary

Cigna on July 10 said it will add three new Humira biosimilars — Boehringer Ingelheim’s Cyltezo and Sandoz’s Hyrimoz and Adalimumab-adaz (the unbranded equivalent of Hyrimoz) — to its national preferred, standard, performance, and legacy commercial formularies controlled by Cigna Pharmacy Management. The products will be preferred at parity with Humira. The company also said it will cover Organon’s Hadlima as a preferred drug on its value, advantage, and total savings formularies. Cigna Pharmacy Management, which handles drug benefits for Cigna Healthcare, currently manages 11.2 million pharmacy lives. Humira is a preferred product that requires utilization management, such as step therapy and/or prior authorization, for 67% of Cigna’s pharmacy lives.

SOURCE: MMIT Analytics, as of 7/12/23

0 Comments
© 2024 MMIT
Jinghong Chen

Jinghong Chen Reporter

Jinghong has been producing infographics and data stories on employer-sponsored insurance, public health insurance programs and prescription drug coverage for AIS Health’s Health Plan Weekly and Radar on Drug Benefits since 2018. She also manages AIS Health’s annual executive compensation database for top insurers and Blue Cross and Blue Shield affiliates. Before joining AIS Health, she interned at WBEZ, Al Jazeera English and The New York Times Chinese. She graduated from Missouri School of Journalism with a focus on data journalism and international reporting.

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today